Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Human Genetics01:28

Human Genetics

1.4K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
1.4K
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

486
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
486
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

1.8K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
1.8K
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

437
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
437
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

466
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
466
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

806
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
806

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sexual function despite hyperprolactinemia: a 24-month analysis of paliperidone palmitate versus haloperidol decanoate.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry·2026
Same author

Real-world effectiveness and safety of intranasal esketamine for treatment-resistant depression: data from the enTRD registry.

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same author

Co-expression-based models improve eQTL predictions for transcriptome-wide association studies and highlight new schizophrenia-associated genes.

Nature genetics·2026
Same author

Suicidality phenotypes reflect both shared and distinct genetic factors.

medRxiv : the preprint server for health sciences·2026
Same author

Insulin Resistance as a Mediator of Suicide Risk in Bipolar Disorder: A Neurobiological and Imaging Study.

Bipolar disorders·2026
Same author

GWAS meta-analysis of cerebrospinal fluid Alzheimer's biomarkers reveals loci regulating lipids, brain volume and autophagy.

Nature communications·2026

Related Experiment Video

Updated: Jan 14, 2026

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

39.6K

Schizophrenia Genetics Modulates Clinical Depressive Features.

Alessandro Serretti1,2, Daniel Souery3, Siegfried Kasper4,5

  • 1Department of Medicine and Surgery, Kore University of Enna, Enna, Italy.

American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics
|October 20, 2025
PubMed
Summary

Genetic liability for schizophrenia (SCZ) influences major depressive disorder (MDD) presentation. Higher SCZ polygenic scores (PGS) are linked to increased symptom severity and functional impairment in MDD patients.

Keywords:
antidepressantsmajor depressionpolygenic risk scoresschizophreniatreatment resistant depression (TRD)

More Related Videos

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.2K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.4K

Related Experiment Videos

Last Updated: Jan 14, 2026

The Forced Swim Test as a Model of Depressive-like Behavior
05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

39.6K
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.2K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.4K

Area of Science:

  • Psychiatry
  • Genetics
  • Clinical Research

Background:

  • Major depressive disorder (MDD) exhibits significant clinical heterogeneity.
  • Polygenic scores (PGS) are emerging tools for quantifying genetic liability across psychiatric disorders.
  • The genetic overlap between schizophrenia (SCZ) and MDD is an area of active investigation.

Purpose of the Study:

  • To investigate the impact of SCZ genetic liability, measured by SCZ-PGS, on MDD clinical phenotypes.
  • To assess the association between SCZ-PGS and MDD symptom severity, comorbidities, and treatment outcomes.
  • To validate findings in independent patient cohorts.

Main Methods:

  • Utilized SCZ-PGS derived from the latest SCZ genome-wide association study (GWAS).
  • Analyzed data from 1060 MDD patients in the GSRD sample, with replication in 1503 MDD patients from the STAR*D sample.
  • Assessed depressive symptom severity, functional impairment, and comorbid conditions.

Main Results:

  • Higher SCZ-PGS was significantly associated with increased severity of depressive symptoms, including sadness, tension, lassitude, pessimism, and suicidality.
  • Elevated SCZ-PGS correlated with greater functional impairment across social, familial, and work domains.
  • SCZ-PGS showed a modest but significant association with poorer treatment outcomes and increased anxiety comorbidity.

Conclusions:

  • SCZ genetic liability contributes to the clinical heterogeneity observed in MDD.
  • Elevated SCZ-PGS may serve as a genetic marker for more severe depressive presentations and associated comorbidities.
  • Further research can explore the clinical utility of SCZ-PGS in predicting MDD course and severity.